Literature DB >> 23172928

Risk stratification by 24-hour ambulatory blood pressure and estimated glomerular filtration rate in 5322 subjects from 11 populations.

José Boggia1, Lutgarde Thijs, Yan Li, Tine W Hansen, Masahiro Kikuya, Kristina Björklund-Bodegård, Takayoshi Ohkubo, Jørgen Jeppesen, Christian Torp-Pedersen, Eamon Dolan, Tatiana Kuznetsova, Katarzyna Stolarz-Skrzypek, Valérie Tikhonoff, Sofia Malyutina, Edoardo Casiglia, Yuri Nikitin, Lars Lind, Emma Schwedt, Edgardo Sandoya, Kalina Kawecka-Jaszcz, Jan Filipovsky, Yutaka Imai, Jiguang Wang, Hans Ibsen, Eoin O'Brien, Jan A Staessen.   

Abstract

No previous study addressed whether in the general population estimated glomerular filtration rate (eGFR [Chronic Kidney Disease Epidemiology Collaboration formula]) adds to the prediction of cardiovascular outcome over and beyond ambulatory blood pressure. We recorded health outcomes in 5322 subjects (median age, 51.8 years; 43.1% women) randomly recruited from 11 populations, who had baseline measurements of 24-hour ambulatory blood pressure (ABP(24)) and eGFR. We computed hazard ratios using multivariable-adjusted Cox regression. Median follow-up was 9.3 years. In fully adjusted models, which included both ABP(24) and eGFR, ABP(24) predicted (P≤0.008) both total (513 deaths) and cardiovascular (206) mortality; eGFR only predicted cardiovascular mortality (P=0.012). Furthermore, ABP(24) predicted (P≤0.0056) fatal combined with nonfatal events as a result of all cardiovascular causes (555 events), cardiac disease (335 events), or stroke (218 events), whereas eGFR only predicted the composite cardiovascular end point and stroke (P≤0.035). The interaction terms between ABP(24) and eGFR were all nonsignificant (P≥0.082). For cardiovascular mortality, the composite cardiovascular end point, and stroke, ABP(24) added 0.35%, 1.17%, and 1.00% to the risk already explained by cohort, sex, age, body mass index, smoking and drinking, previous cardiovascular disease, diabetes mellitus, and antihypertensive drug treatment. Adding eGFR explained an additional 0.13%, 0.09%, and 0.14%, respectively. Sensitivity analyses stratified for ethnicity, sex, and the presence of hypertension or chronic kidney disease (eGFR <60 mL/min per 1.73 m(2)) were confirmatory. In conclusion, in the general population, eGFR predicts fewer end points than ABP(24). Relative to ABP(24), eGFR is as an additive, not a multiplicative, risk factor and refines risk stratification 2- to 14-fold less.

Entities:  

Mesh:

Year:  2012        PMID: 23172928      PMCID: PMC3607362          DOI: 10.1161/HYPERTENSIONAHA.112.197376

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  42 in total

1.  Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study.

Authors:  Takayoshi Ohkubo; Atsushi Hozawa; Junko Yamaguchi; Masahiro Kikuya; Kaori Ohmori; Mari Michimata; Mitsunobu Matsubara; Junichiro Hashimoto; Haruhisa Hoshi; Tsutomu Araki; Ichiro Tsuji; Hiroshi Satoh; Shigeru Hisamichi; Yutaka Imai
Journal:  J Hypertens       Date:  2002-11       Impact factor: 4.844

2.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

3.  Are published characteristics of the ambulatory blood pressure generalizable to rural Chinese? The JingNing population study.

Authors:  Yan Li; Ji-Guang Wang; Pingjin Gao; Huifeng Guo; Tim Nawrot; Guliang Wang; Yuesheng Qian; Jan A Staessen; Dingliang Zhu
Journal:  Blood Press Monit       Date:  2005-06       Impact factor: 1.444

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  eGFR is associated with subclinical atherosclerosis independent of albuminuria: the Dong-gu Study.

Authors:  Seong-Woo Choi; Hye-Yeon Kim; Young-Hoon Lee; So-Yeon Ryu; Sun-Seog Kweon; Jung-Ae Rhee; Jin-Su Choi; Min-Ho Shin
Journal:  Atherosclerosis       Date:  2010-07-25       Impact factor: 5.162

6.  Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population.

Authors:  Brad C Astor; Stein I Hallan; Edgar R Miller; Edwina Yeung; Josef Coresh
Journal:  Am J Epidemiol       Date:  2008-04-02       Impact factor: 4.897

7.  Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension.

Authors:  P Verdecchia; G Schillaci; C Borgioni; A Ciucci; S Pede; C Porcellati
Journal:  Hypertension       Date:  1998-12       Impact factor: 10.190

8.  Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-year cardiovascular risk.

Authors:  Masahiro Kikuya; Tine W Hansen; Lutgarde Thijs; Kristina Björklund-Bodegård; Tatiana Kuznetsova; Takayoshi Ohkubo; Tom Richart; Christian Torp-Pedersen; Lars Lind; Hans Ibsen; Yutaka Imai; Jan A Staessen
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690

Review 9.  Kinetic serum creatinine assays. II. A critical evaluation and review.

Authors:  L D Bowers; E T Wong
Journal:  Clin Chem       Date:  1980-04       Impact factor: 8.327

10.  GFR, proteinuria and circadian blood pressure.

Authors:  Rajiv Agarwal; Robert P Light
Journal:  Nephrol Dial Transplant       Date:  2009-02-27       Impact factor: 5.992

View more
  7 in total

1.  Association of kidney function and albuminuria with prevalent and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Minxuan Huang; Kunihiro Matsushita; Yingying Sang; Shoshana H Ballew; Brad C Astor; Josef Coresh
Journal:  Am J Kidney Dis       Date:  2014-08-21       Impact factor: 8.860

2.  Management of Resistant Hypertension: Do Not Give Up on Medication.

Authors:  Eric Judd; David A Calhoun
Journal:  Nephrol Self Assess Program       Date:  2014-03

Review 3.  Ambulatory blood pressure in chronic kidney disease.

Authors:  Debbie L Cohen; Yonghong Huan; Raymond R Townsend
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

4.  Progression of glomerular filtration rate reduction determined in conscious Dahl salt-sensitive hypertensive rats.

Authors:  Allen W Cowley; Robert P Ryan; Terry Kurth; Meredith M Skelton; Daniel Schock-Kusch; Norbert Gretz
Journal:  Hypertension       Date:  2013-04-29       Impact factor: 10.190

5.  Ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations.

Authors:  Yan Li; Fang-Fei Wei; Lutgarde Thijs; José Boggia; Kei Asayama; Tine W Hansen; Masahiro Kikuya; Kristina Björklund-Bodegård; Takayoshi Ohkubo; Jørgen Jeppesen; Yu-Mei Gu; Christian Torp-Pedersen; Eamon Dolan; Yan-Ping Liu; Tatiana Kuznetsova; Katarzyna Stolarz-Skrzypek; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Kalina Kawecka-Jaszcz; Luis Mena; Gladys E Maestre; Jan Filipovský; Yutaka Imai; Eoin O'Brien; Ji-Guang Wang; Jan A Staessen
Journal:  Circulation       Date:  2014-06-06       Impact factor: 29.690

Review 6.  Blood pressure control and primary prevention of stroke: summary of the recent clinical trial data and meta-analyses.

Authors:  Zbigniew Gaciong; Maciej Siński; Jacek Lewandowski
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

Review 7.  Ambulatory blood pressure monitoring over 24 h: A Latin American Society of Hypertension position paper-accessibility, clinical use and cost effectiveness of ABPM in Latin America in year 2020.

Authors:  Ramiro A Sánchez; José Boggia; Ernesto Peñaherrera; Weimar Sebba Barroso; Eduardo Barbosa; Raúl Villar; Leonardo Cobos; Rafael Hernández Hernández; Jesús Lopez; José Andrés Octavio; José Z Parra Carrillo; Agustín J Ramírez; Gianfranco Parati
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-02-12       Impact factor: 3.738

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.